Neoantigen vaccine is a new field of research in tumor immunotherapy, and some studies have been conducted with success on Melanoma and glioblastoma. Nearly 80% of lung cancers are diagnosed in an advanced stage (IIIB, and IV) and EGFR mutant non-small cell lung cancer will be resistant after targeted drug treatment. Neoantigen vaccine is a new treatment method for lung cancer, especially for patients with drug resistance.
Name: neoantigen vaccine + EGFR-TKI
Name: neoantigen vaccine + anti-angioge
Description: Safety
Measure: Adverse events evaluated and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03. Time: 24 monthsDescription: PFS as measured in accordance with the Response Evaluation Criteria In Solid Tumours (RECIST) version 1.1
Measure: Progression-free Survival (PFS) Time: Up to 2 yearsDescription: OS as measured in accordance with the Response Evaluation Criteria In Solid Tumours (RECIST) version 1.1
Measure: Overall survival (OS) Time: Up to 2 yearsDescription: DCR as measured in accordance with the Response Evaluation Criteria In Solid Tumours (RECIST) version 1.1
Measure: Disease Control Rate(DCR) Time: Up to 12 weeksAllocation: Non-Randomized
Parallel Assignment
There is one SNP
Inclusion Criteria: 1. Histologically confirmed locally advanced or metastatic non-small-cell lung cancer (stage III or stage IV). 2. With EGFR-TKI sensitive mutations and no T790M. --- T790M ---